Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
Age-related macular degeneration (AMD) affects the macula in the eye. This is the central part of the retina. It is needed for sharp, clear vision and activities like reading and driving. AMD is the leading cause of vision loss in Americans 60 years of age and older. An advanced form of AMD is called geographic atrophy or GA. It happens when light-sensitive cells in the macula die so much that central vision decreases.
To learn more about geographic atrophy associated with age-related macular degeneration.
Adults at least 55 years old with a certain kind of GA. They must be enrolled in study 08-EI-0102, 08-EI-0169, 08-EI-0043, 12-EI-0042, or 11-EI-0147 but no other studies.
Participants will be screened with medical history, physical exam, and an eye exam.
Participants will have study visits every 3 months for 15 months, then every 6 months. They will be in the study almost 4 years.
Visits will last about 8 hours. At each visit, participants may have:
Medical and eye history. Participants will answer questions about their general health and eye health. They may answer written questions about how their eye problems affect their life.
Eye exam and photographs. Eye pressure will be measured and eye movements will be checked. Pupils will be dilated with drops. The thickness of the retina will be measured and photos of the eye may be taken.
Age-Related Macular Degeneration
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration|
- The primary outcome is the difference in the mean rate of change in area of GA in the study eye based on digital grading of FAF images by an external Reading Center. [ Time Frame: 45 months ]
- Secondary outcomes include differences in study eyes for the following: mean rate of change in area of GA based on digital grading of color fundus images, mean changes in BCVA, mean changes in central retinal thickness on OCT, and the proportion... [ Time Frame: 45 months ]
|Study Start Date:||October 11, 2016|
|Estimated Study Completion Date:||June 21, 2020|
|Estimated Primary Completion Date:||June 21, 2020 (Final data collection date for primary outcome measure)|
Objective: Age-related macular degeneration (AMD), the leading cause of blindness in people over age 65 in the United States, is a heterogeneous clinical entity in which retinal degeneration occurs predominantly in the macula in the context of aging and leads to impairment of central visual acuity (VA). AMD occurs in two general forms, one of which involves choroidal neovascularization (CNV) with subsequent formation of a disciform scar. This is often referred to as the neovascular or wet form. A second form, the subject of this study, is termed dry atrophic macular degeneration or otherwise geographic atrophy (GA) and involves a slow progressive atrophy of retinal pigment epithelial (RPE) cells and photoreceptors in the macula, also resulting in central vision loss. GA is estimated to affect up to one million people in the U.S. and there is no current treatment that can prevent its onset or retard its progression. While the etiology of GA is not completely understood, inflammatory processes involving the activation of resident immune cells of the retina called microglia are likely to contribute. The objective of this study is to study the progression of GA so as to be able to characterize in quantitative terms the natural progression of GA in patients not receiving any directed treatment; there is currently no approved treatment for GA.
Study Population: Twenty-five (25) participants with unilateral or bilateral GA associated with AMD will be enrolled.
Design: This prospective, natural history study will follow participants with GA associated with AMD.
Outcome Measures: The primary outcome is the rate of change in area of GA based on grading by an external Reading Center of fundus autofluorescence (FAF) images in the assigned study eye. The primary outcome will be calculated for 45 months as compared to baseline. Secondary outcomes will include changes in best-corrected visual acuity (BCVA), rate of change in area of GA based on fundus photography and development of exudative AMD ascertained using optical coherence tomography (OCT) and changes in macular sensitivity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02941263
|Contact: Katherine M Hall, R.N.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Wai T Wong, M.D.||National Eye Institute (NEI)|